Copyright: ©Author(s) 2026.
World J Clin Oncol. May 24, 2026; 17(5): 116662
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.116662
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.116662
Figure 5 Immunohistochemical expression of the low-molecular-weight isoform of caldesmon in formalin-fixed, paraffin-embedded tissues from resected breast cancers.
A: Luminal A breast cancer sample showing strong cytoplasmic low-molecular-weight isoform of caldesmon (l-CAD) positivity; B: Sample from luminal A breast cancer showing negative l-CAD staining; C: HER-2 sample showing strong positive l-CAD expression; D: HER-2 sample showing moderate l-CAD expression; E and F: Triple-negative breast cancer sample showing positive to strong positive l-CAD expression.
- Citation: AlNuaimi A, Nair VA, Al-Khayyal N, Suliman A, Bou Malhab LJ, Hamoudi R, Hamad M, Talaat IM, Abdel-Rahman WM. Overexpression of low-molecular-weight caldesmon is associated with aggressive phenotypes and epithelial-mesenchymal transition in breast cancer cells. World J Clin Oncol 2026; 17(5): 116662
- URL: https://www.wjgnet.com/2218-4333/full/v17/i5/116662.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i5.116662